Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 0482

Next Previous
Drug Profile

MK 0482

Alternative Names: MK-0482

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; Presage Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action LILRB4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
  • Phase 0 Head and neck cancer; Soft tissue sarcoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-0 development in Solid-tumours(Combination therapy) in USA (Intratumoural, Injection)
  • 31 May 2024 Updated efficacy and safety data from phase Ib trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and safety data from phase Ib trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top